LEVAMISOLE IMMUNOTHERAPY OF EXPERIMENTAL TRANSITIONAL CELL-CARCINOMA

  • 1 January 1979
    • journal article
    • research article
    • Vol. 16  (4) , 286-288
Abstract
Levamisole, in doses comparable to those under clinical investigation, significantly (P < 0.02) delayed the onset of transplanted transitional cell carcinoma [MBA2] of C3H mice. The growth of transplanted tumors was inhibited and animal survival prolonged with levamisole treatment. Further progress in the immunotherapy of transitional cell carcinoma may be aided by such models.

This publication has 2 references indexed in Scilit: